According to a recent LinkedIn post from Resolution Therapeutics, the company intends to have a significant presence at the upcoming EASL Congress in Barcelona, a key event in hepatology. The post names senior leaders from translational science, medical, operations, and strategy who plan to attend, suggesting coordinated scientific and clinical engagement.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post highlights ongoing work on the Phase I/II EMERALD trial evaluating RTX001, described as an engineered regenerative macrophage therapy for patients with end-stage liver disease. The company indicates it is on track to deliver interim results later this year, which could represent a meaningful clinical inflection point and may influence Resolution Therapeutics’ strategic options, partnerships, and valuation expectations in the liver disease and cell therapy space.